Axonics has announced the first patient implants in Canada with Axonics F15, the company’s newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system.
The University of Alberta (Edmonton, Canada) implanted four patients this week with the Axonics F15, according to a company press release. The four patients were programmed at stimulation amplitudes between 0.95mA and 0.30mA, resulting in an expected battery longevity in the body ranging from 18 years to more than 22 years.
The Axonics F15 received regulatory approval from Health Canada following its earlier US Food and Drug Administration (FDA) approval. The comprehensive US commercial launch of the system commenced in the second quarter of 2022, the release adds.
“The approval of the Axonics recharge-free system is welcome news for patients in Canada suffering from bladder and bowel dysfunction,” said Gary Gray (University of Alberta, Edmonton, Canada). “I am excited to now offer patients a recharge-free option that significantly increases device longevity in the body alongside the rechargeable Axonics SNM system that has helped so many of my patients.”
